The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer - PubMed
5 hours ago
- #metastatic colorectal cancer
- #etrumadenant
- #regorafenib
- The ARC-9 study compared etrumadenant-based therapy (EZFB) with regorafenib in third-line metastatic colorectal cancer (mCRC) patients.
- EZFB showed significant improvement in progression-free survival (6.2 months vs. 2.1 months) and overall survival (19.7 months vs. 9.5 months) compared to regorafenib.
- The confirmed overall response rate was higher with EZFB (17%) than regorafenib (3%).
- Grade ≥3 treatment-emergent adverse events were more common with EZFB (82%) than regorafenib (49%), but discontinuation rates were lower (5% vs. 17%).
- EZFB demonstrated a manageable safety profile and clinically meaningful survival benefits, warranting further investigation.